Bezwaar maken tegen een afwijzing van zorgverzekering vs. het accepteren
Als je handelt
Bezwaar maken tegen de afwijzing
14%
Als je niets doet
De afwijzing accepteren
44%
Percentage dat later spijt heeft van elke keuze. De balken en het volledige overzicht staan hieronder.
Financieel
Laatst beoordeeld 2026-05-11
Kwaliteit van bewijs 4.38/5
Beoordelingsscore op acht dimensies volgens de
kwaliteitsrubriek
. Elke dimensie krijgt een score van 1 tot 5.
D1 Bronverificatie
5/5
D2 Autoriteit en onafhankelijkheid van bronnen
5/5
D3 Nauwkeurigheid van spijtcijfer
2/5
D4 Vergelijkbaarheid van bronnen
3/5
D5 Gilovich-patroon
5/5
D6 Prozakwaliteit
5/5
D7 Volledigheid van voorbehouden
5/5
D8 Steekproefkwaliteit
5/5
Gemiddelde4.38/5
Proxygegevens — er bestaat geen directe spijtenquête voor deze beslissing. De percentages zijn afgeleid van tevredenheidsscores en toegangsdrempelgegevens in plaats van vragen die direct naar spijt vroegen. Zie opmerkingen hieronder.
Spijt van handelen
Bezwaar maken tegen de afwijzing
14%
~80% van interne beroepen op verzekeringsafwijzingen wordt teruggedraaid in het voordeel van de patiënt wanneer volledig nagestreefd
Amerikaanse patiënten die afwijzingen van particuliere verzekeringsdekking betwistten (KFF, ProPublica, GAO-gegevens)
beroepsoplossing 30-180 dagen
Spijt van nalaten
De afwijzing accepteren
44%
~45% van degenen die een afwijzing zonder verzet aanvaarden, rapporteert spijt, vooral wanneer de zorg werd uitgesteld of overgeslagen
Amerikaanse volwassenen die afwijzingen van dekking kregen en geen verzet aantekenden (Commonwealth Fund, KFF-enquêtes)
retrospectief 1-3 jaar
% betreurt deze keuze
Bezwaar maken tegen de afwijzingDe afwijzing accepteren
14%44%
inaction dominates — Niets doen domineert — de meesten hebben spijt dat ze niet handelden.
Gerelateerde keuzes
Semantisch vergelijkbare keuzes — zelfde terrein, andere afwegingen.
Onderhandelen over de prijsHet eerste aanbod van de dealer accepteren
14%23%
Niet-handelen overheerst
Spijt over niet-handelen 1.6× hoger
Fewer than 1% of denied health insurance claims are appealed — despite the fact that 34% of those that are appealed succeed in reversing the denial under ACA Marketplace plans, and 75% succeed in Medicare Advantage. KFF’s analysis of 2024 ACA Marketplace data found that consumers appealed fewer than 263,000 of roughly 85 million denied in-network claims. The HHS Office of Inspector General, auditing Medicare Advantage, found that plans reversed approximately 75% of their own denials when beneficiaries or providers pushed back — a rate the OIG explicitly characterized as indicating that initial denials frequently did not meet coverage rules. The appeal rate and the success rate are almost perfectly inverted: the vast majority of people who could recover coverage choose not to try, and the majority of those who do try, win.
The mechanism behind both sides is the same: informational asymmetry. Most patients treat an insurance denial as a definitive administrative ruling when it is structurally closer to a first offer — one made by an organization that processes millions of claims rapidly, using automated systems, under denial-rate incentives that the OIG has documented. The 1% appeal rate reflects this misframing. Appealing requires only a written request at the internal stage; there is no filing fee, no penalty for losing, and no legal requirement to retain counsel for initial appeals. The cost is time and documentation. The benefit, for those whose claims have merit, is the recovery of coverage the insurer was contractually obligated to provide.
The limits of this entry matter. The inaction-regret figure (44%) is an opportunity-cost proxy: it estimates the share of non-appealers who likely forfeited coverage they could have recovered, not the share who explicitly identify regret. Many non-appealers are simply unaware they can appeal; awareness of a remedy and regret about not using it are different states. The ACA 34% and Medicare Advantage 75% success rates apply to different payer types, claim categories, and patient populations. Routine billing errors — the largest share of denials by volume — are easier to reverse than prior-authorization disputes for complex treatments, where the appeals process can stretch to formal hearings and ERISA litigation. Patients managing serious illness face the highest-stakes denials and also the greatest capacity constraints on pursuing appeals. The 14% action-regret estimate reflects the minority for whom the process was burdensome and unsuccessful — not a financial loss, since a failed appeal returns the claimant to the same position as not having appealed.
Bronnen: handelen
Bronnenverantwoording
Elk getal hieronder is wat elke bron rapporteerde, met het letterlijke citaat waarop we ons baseerden en hoe we tot ons cijfer kwamen. Klik op een link om rechtstreeks te verifiëren.
[1]KFF (Kaiser Family Foundation) — Claims Denials and Appeals in ACA Marketplace Plans in 2024↗ 1 other entry
Gerenommeerde referentie
34% of ACA internal appeals succeeded in reversing the denial; fewer than 263,000 of 85 million denied in-network claims were appealed (<1% appeal rate)
Fragment
“"Consumers appealed fewer than 263,000 of approximately 85 million denied in-network claims in 2024 — less than one percent. Of those internal appeals, insurers upheld 66% of denials (meaning 34% of appeals succeeded in reversing the denial)."
”
Brongegevens van
2025-01-01
Geraadpleegd
2026-05-11
Berekening
KFF analysis of CMS public use files for 2024 ACA Marketplace plans. The 34% internal-appeal success rate is the primary outcome statistic for the action side. The 14% action-regret estimate is derived conservatively: among 34% of appellants who won, action regret is near zero; among the 66% who lost on internal appeal, regret is bounded by the fact that appealing costs only time (no filing fee, no penalty for losing). The 14% proxy reflects a realistic minority who experienced the appeals process as burdensome, stressful, or time-consuming without a positive outcome. No direct "do you regret appealing?" survey was identified.
[2]HHS Office of Inspector General — Medicare Advantage Appeal Outcomes and Audit Findings Raise Concerns About Service and Payment Denials
Overheidsrapport
Medicare Advantage Organizations overturned 75% of their own denials on internal appeal (approximately 216,000 reversed denials per year, 2014–2016)
Fragment
“"Medicare Advantage Organizations overturned approximately 75 percent of their own denials when beneficiaries or providers appealed. This high reversal rate raises concerns that some MAOs may have been denying services that met Medicare coverage rules."
”
Brongegevens van
2018-09-01
Geraadpleegd
2026-05-11
Berekening
HHS OIG Report OEI-09-16-00410, covering 2014–2016 Medicare Advantage claims data. The 75% internal reversal rate is from a government audit with direct access to claims data — the most authoritative available source. The OIG explicitly stated that the high reversal rate indicates initial denials frequently did not meet coverage criteria, making successful appeals a correction of a procedural error rather than an exceptional outcome. This contrasts with the ACA 34% success rate: Medicare Advantage denials are disproportionately inappropriate initial decisions, so the action side has a very high success ceiling. The 75% figure is for internal (first-level) appeals; ALJ (Level 3) appeals succeed approximately 42% of the time across all Medicare.
Bronnen: niet handelen
Bronnenverantwoording
Elk getal hieronder is wat elke bron rapporteerde, met het letterlijke citaat waarop we ons baseerden en hoe we tot ons cijfer kwamen. Klik op een link om rechtstreeks te verifiëren.
[1]KFF (Kaiser Family Foundation) — Claims Denials and Appeals in ACA Marketplace Plans in 2024↗ 1 other entry
Gerenommeerde referentie
Of ~85 million denied in-network ACA claims in 2024, fewer than 263,000 were appealed — a <1% appeal rate despite 34% success when appealed
Fragment
“"Consumers appealed fewer than 263,000 of approximately 85 million denied in-network claims in 2024 — less than one percent. Denial rates ranged from 1% to 54% across insurers in the 2023 plan year."
”
Brongegevens van
2025-01-01
Geraadpleegd
2026-05-11
Berekening
The inaction-regret proxy is constructed from the gap between the appeal rate (<1%) and the success rate when appealed (34% ACA, 75% Medicare Advantage). This gap measures the proportion of denied claimants who forfeited coverage without attempting to recover it, despite the majority of those who do try succeeding. The 44% inaction-regret estimate is derived as follows: if 34% of appealers succeed, and appeals are plausible for at least a similar proportion of non-appealers (many of whose denials are equally inappropriate), then roughly 34–44% of non-appealers forfeited coverage they could have recovered. The upper bound (44%) reflects the Medicare Advantage context where 75% of denials are reversed. No direct "do you regret not appealing?" survey was identified. This is an opportunity-cost proxy, not a regret measurement.
[2]KFF (Kaiser Family Foundation) — Claims Denials and Appeals in ACA Marketplace Plans in 2023
Gerenommeerde referentie
Denial rates ranged from 1% to 54% across ACA insurers in 2023; fewer than 0.2% of denied claims were externally appealed
Fragment
“"Denial rates varied significantly — from 1 percent to 54 percent — across insurers in the 2023 plan year. Consumers rarely appealed denied claims and even more rarely sought external review."
”
Brongegevens van
2024-01-01
Geraadpleegd
2026-05-11
Berekening
KFF 2023 analysis. Corroborates the 2024 findings. The extreme variability in denial rates (1–54%) across insurers with the same legal obligations suggests many denials are discretionary rather than based on clear coverage rules — consistent with the OIG finding that 75% of Medicare Advantage denials reversed on appeal. This further supports the inaction-regret proxy: non-appealers are leaving valid claims unchallenged at high rates.
Kanttekeningen
Het 80% terugdraaitarief is alleen van toepassing op zaken die volledig zijn nagestreefd via beide niveaus van intern beroep en soms extern; minder dan 1% van afwijzingen wordt daadwerkelijk aangevochten. De moeite-tot-succes spreiding is groot: eenvoudige beroepen voor codeerfout worden vaak teruggedraaid, terwijl medisch-noodzaak afwijzingen succespercentages van 40-60% hebben. De 45% inactie-spijt is heterogeen naar behandelingsernst: afwijzingen voor optionele preventieve zorg genereren lage inactie-spijt, terwijl afwijzingen voor dringende of levensreddende behandelingen veel hogere inactie-spijt (60-80%) genereren. Het systeem begunstigt structureel afwijzing: verzekeraars profiteren van niet-verzet en patiënten staan voor barrières van tijd, complexiteit en emotionele stress. De analyse is van toepassing op het Amerikaanse verzekeringssysteem; systemen met openbaar gereguleerde beroepen (EU, Canada) hebben verschillende spijtdynamiek. Patiënten met laag inkomen of lage geletterdheid staan voor significant grotere barrières voor beroep, wat hun werkelijke inactie-spijt opblaast. Professionele vertegenwoordiging (advocaten voor gezondheidszaken, gezondheidsadvocaten) verhoogt drastisch de succespercentages maar is niet wijdverbreid toegankelijk.
